Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

References

• Perica K, Varela JC, Oelke M, Schneck J. Adoptive T-cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):1. doi:10.5041/RMMJ.10179.
   Google Scholar
• Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21(1):807–25. doi:10.1146/annurev.immunol.21.120601.141135.
   PubMedGoogle Scholar
• Park JH, Brentjens RJ. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T-cells. Discov Med. 2010;9:277.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kawakami Y. Human tumor antigens recognized by T-cells. Curr Opin Immunol. 1996;8(5):628–636. doi:10.1016/S0952-7915(96)80078-1.
   PubMed Web of Science ®Google Scholar
• Strati P, Neelapu SS. Chimeric antigen receptor–engineered T-cell therapy in lymphoma. Curr Oncol Rep. 2019;21(5):1–7. doi:10.1007/s11912-019-0789-z.
   Web of Science ®Google Scholar
• Zhang E, Xu H. A new insight in chimeric antigen receptor-engineered T-cells for cancer immunotherapy. J Hematol Oncol. 2017;10(1):1–11. doi:10.1186/s13045-016-0379-6.
   PubMedGoogle Scholar
• Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492–500. doi:10.1038/leu.2015.247.
   PubMed Web of Science ®Google Scholar
• Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149(3):960–968. doi:10.1016/0006-291X(87)90502-X.
   PubMed Web of Science ®Google Scholar
• Gross G, Gorochov G, Waks T, Eshhar Z, editors. Generation of effector T-cells expressing chimeric T-cell receptor with antibody type-specificity. Transplant Proc. Israel. 1989;21(1 Pt 1):127–130.
   Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Nat Acad Sci. 1989;86(24):10024–10028. doi:10.1073/pnas.86.24.10024.
   PubMed Web of Science ®Google Scholar
• Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong JF, Zhang C, et al. Recent advances in CAR-T-cell engineering. J Hematol Oncol. 2020;13(1):1–19. doi:10.1186/s13045-020-00910-5.
   PubMed Web of Science ®Google Scholar
• Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor‐expressing T-cells. Immunol Rev. 2014;257(1):107–126. doi:10.1111/imr.12131.
   PubMed Web of Science ®Google Scholar
• Guedan S, Calderon H, Posey JA, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther-Met Clin Dev. 2019;12:145–156. doi:10.1016/j.omtm.2018.12.009.
   PubMed Web of Science ®Google Scholar
• Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY, Zhao W. Car-T design: elements and their synergistic function. EBioMedicine. 2020;58:102931. doi:10.1016/j.ebiom.2020.102931.
   PubMed Web of Science ®Google Scholar
• Zajc CU, Salzer B, Taft JM, Reddy ST, Lehner M, Traxlmayr MW. Driving CARs with alternative navigation tools–the potential of engineered binding scaffolds. Febs J. 2021;288(7):2103–2118. doi:10.1111/febs.15523.
   PubMed Web of Science ®Google Scholar
• Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RM, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, et al. Targeting of aberrant αvβ6 integrin expression in solid tumors using chimeric antigen receptor-engineered T Cells. Mol Ther. 2017;25(1):259–273. doi:10.1016/j.ymthe.2016.10.012.
   PubMed Web of Science ®Google Scholar
• Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T-cells with a chimeric NKG2D receptor. Cancer Res. 2006;66(11):5927–5933. doi:10.1158/0008-5472.CAN-06-0130.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125–135. doi:10.1158/2326-6066.CIR-14-0127.
   PubMed Web of Science ®Google Scholar
• Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O’Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203–211. doi:10.1097/01.cji.0000161397.96582.59.
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028–7038. doi:10.4049/jimmunol.180.10.7028.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, et al. Retargeting of human T-cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180(7):4901–4909. doi:10.4049/jimmunol.180.7.4901.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu J, Zhong JF, Zhang X. Engineering car-T-cells. Biomarker Res. 2017;5(1):1–6. doi:10.1186/s40364-017-0081-z.
   PubMedGoogle Scholar
• Elazar A, Chandler NJ, Davey AS, Weinstein JY, Nguyen JV, Trenker R, Cross RS, Jenkins MR, Call MJ, Call ME. De novo-designed transmembrane domains tune engineered receptor functions. Elife. 2022;11:e75660. doi:10.7554/eLife.75660.
   PubMed Web of Science ®Google Scholar
• Chandran SS, Klebanoff CA. T-Cell receptor‐based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev. 2019;290(1):127–147. doi:10.1111/imr.12772.
   PubMed Web of Science ®Google Scholar
• Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021;14(697):eabe2606. doi:10.1126/scisignal.abe2606.
   PubMed Web of Science ®Google Scholar
• Wu L, Wei Q, Brzostek J, Gascoigne NR. Signaling from T-cell receptors (TCRs) and chimeric antigen receptors (CARs) on T-cells. Cell Mol Immunol. 2020;17(6):600–612. doi:10.1038/s41423-020-0470-3.
   PubMed Web of Science ®Google Scholar
• Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol. 2006;24(1):419–466. doi:10.1146/annurev.immunol.23.021704.115658.
   PubMedGoogle Scholar
• Becker ML, Near R, Mudgett-Hunter M, Margolies MN, Kubo RT, Kaye J, Hedrick SM. Expression of a hybrid immunoglobulin-T-cell receptor protein in transgenic mice. Cell. 1989;58(5):911–921. doi:10.1016/0092-8674(89)90943-4.
   PubMed Web of Science ®Google Scholar
• Hogquist KA, Jameson SC. The self-obsession of T-cells: how TCR signaling thresholds affect fate ’decisions’ and effector function. Nat Immunol. 2014;15(9):815–823. doi:10.1038/ni.2938.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T-cells tumor recognition by ROR1-specific CARs. Clin Cancer Res. 2013;19(12):3153–3164. doi:10.1158/1078-0432.CCR-13-0330.
   PubMed Web of Science ®Google Scholar
• Huang J, Brameshuber M, Zeng X, Xie J, Li Q-J, Chien Y-H, Valitutti S, Davis M. A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4+ T-cells. Immunity. 2013;39(5):846–857. doi:10.1016/j.immuni.2013.08.036.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Terakura S, Martens AC, Van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, et al. Target antigen density governs the efficacy of anti–CD20-CD28-CD3 ζ chimeric antigen receptor–modified effector CD8 + T cells. J Immunol. 2015;194(3):911–920. doi:10.4049/jimmunol.1402346.
   PubMed Web of Science ®Google Scholar
• Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjöstrand M, Lindenbergh PL, et al. HLA-Independent T-cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28(2):345–352. doi:10.1038/s41591-021-01621-1.
   PubMed Web of Science ®Google Scholar
• Brameshuber M, Kellner F, Rossboth BK, Ta H, Alge K, Sevcsik E, Göhring J, Axmann M, Baumgart F, Gascoigne NRJ, et al. Monomeric TCRs drive T-cell antigen recognition. Nat Immunol. 2018;19(5):487–496. doi:10.1038/s41590-018-0092-4.
   PubMed Web of Science ®Google Scholar
• Chang ZL, Lorenzini MH, Chen X, Tran U, Bangayan NJ, Chen YY. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat Chem Biol. 2018;14(3):317–324. doi:10.1038/nchembio.2565.
   PubMed Web of Science ®Google Scholar
• Davenport A, Cross R, Watson K, Liao Y, Shi W, Prince H, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, et al. Chimeric antigen receptor T-cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Nat Acad Sci. 2018;115(9):E2068–E76. doi:10.1073/pnas.1716266115.
   PubMed Web of Science ®Google Scholar
• Gudipati V, Rydzek J, Doel-Perez I, Gonçalves VDR, Scharf L, Königsberger S, Lobner E, Kunert R, Einsele H, Stockinger H. Inefficient CAR-proximal signaling blunts antigen sensitivity. Nat Immunol. 2020;21(8):848–856. doi:10.1038/s41590-020-0719-0.
   PubMed Web of Science ®Google Scholar
• Brocker T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T-cells. Blood. 2000;96:1999–2001.
   PubMed Web of Science ®Google Scholar
• Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049. doi:10.1002/cti2.1049.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Riddell SR. Engineering CAR-T-cells: design concepts. Trends Immunol. 2015;36(8):494–502. doi:10.1016/j.it.2015.06.004.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Nat Acad Sci. 1993;90(2):720–724. doi:10.1073/pnas.90.2.720.
   PubMed Web of Science ®Google Scholar
• Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med. 2015;240(8):1087–1098. doi:10.1177/1535370215584936.
   Web of Science ®Google Scholar
• Smith AJ, Oertle J, Warren D, Prato D. Chimeric antigen receptor (CAR) T-cell therapy for malignant cancers: summary and perspective. J Cell Immunother. 2016;2(2):59–68. doi:10.1016/j.jocit.2016.08.001.
   Google Scholar
• Imai C, Mihara K, Andreansky M, Nicholson I, Pui C, Geiger T, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676–684. doi:10.1038/sj.leu.2403302.
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol. 2002;20(1):70–75. doi:10.1038/nbt0102-70.
   PubMed Web of Science ®Google Scholar
• Finney HM, Lawson AD, Bebbington CR, Weir ANC. Chimeric receptors providing both primary and costimulatory signaling in T-cells from a single gene product. J Immunol. 1998;161:2791–2797.
   PubMed Web of Science ®Google Scholar
• Acuto O, Michel F. CD28-Mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol. 2003;3(12):939–951. doi:10.1038/nri1248.
   PubMed Web of Science ®Google Scholar
• Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H. Tumor-specific T cell activation by recombinant immunoreceptors: cD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol. 2001;167(11):6123–6131. doi:10.4049/jimmunol.167.11.6123.
   PubMed Web of Science ®Google Scholar
• Jenkins M, Burrell E, Ashwell JD. Antigen presentation by resting B cells. Effectiveness at inducing T-cell proliferation is determined by costimulatory signals, not T-cell receptor occupancy. J Immunol. 1990;144:1585–1590.
   PubMed Web of Science ®Google Scholar
• Krause A, Guo H-F, Latouche J-B, Tan C, Cheung N-K, Sadelain M. Antigen-Dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998;188(4):619–626. doi:10.1084/jem.188.4.619.
   PubMed Web of Science ®Google Scholar
• Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T-cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol. 2004;172(1):104–113. doi:10.4049/jimmunol.172.1.104.
   PubMed Web of Science ®Google Scholar
• Lu P, Lu X-A, Zhang X, Xiong M, Zhang J, Zhou X, Qi F, Yang J, He T. Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process. Am Soc Clin Oncol. 2018;36(15):3041–3041
   Web of Science ®Google Scholar
• Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey JA, Patel PR, Guedan S, Scholler J, Keith B, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T-cells. Immunity. 2016;44(2):380–390. doi:10.1016/j.immuni.2016.01.021.
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T-cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581–590. doi:10.1038/nm.3838.
   PubMed Web of Science ®Google Scholar
• Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 2018;7(6):e1433518. doi:10.1080/2162402X.2018.1433518.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas. Mol Ther. 2018;26(12):2727–2737. doi:10.1016/j.ymthe.2018.09.009.
   PubMed Web of Science ®Google Scholar
• Doherty K. Obe-Cel may mark additional treatment option for R/R B-ALL. 2022.
   Google Scholar
• Abate-Daga D, Davila ML. Car models: next-generation car modifications for enhanced T-cell function. Mol Ther-Oncolytics. 2016;3:16014. doi:10.1038/mto.2016.14.
   PubMed Web of Science ®Google Scholar
• Eggermont LJ, Paulis LE, Tel J, Figdor CG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32(9):456–465. doi:10.1016/j.tibtech.2014.06.007.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–398. doi:10.1158/2159-8290.CD-12-0548.
   PubMed Web of Science ®Google Scholar
• Song D-G, Ye Q, Santoro S, Fang C, Best A, Powell JD. Chimeric NKG2D CAR-expressing T-cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther. 2013;24(3):295–305. doi:10.1089/hum.2012.143.
   PubMed Web of Science ®Google Scholar
• Song D-G, Ye Q, Poussin M, Harms GM, Figini M, Powell JD. CD27 costimulation augments the survival and antitumor activity of redirected human T-cells In vivo. Blood. 2012;119:696–706.
   PubMed Web of Science ®Google Scholar
• Schubert M-L, Schmitt A, Neuber B, Hückelhoven-Krauss A, Kunz A, Wang L, Gern U, Michels B, Sellner L, Hofmann S, et al. Third-generation CAR T-cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T-cells in treated patients. Blood. 2019;134:51. doi:10.1182/blood-2019-125423.
   Web of Science ®Google Scholar
• Künkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas–FasL-dependent AICD. Cancer Immunol Res. 2015;3(4):368–379. doi:10.1158/2326-6066.CIR-14-0200.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: cD28 outperforms combined CD28–OX40 “super-stimulation”. Mol Ther. 2013;21(12):2268–2277. doi:10.1038/mt.2013.192.
   PubMed Web of Science ®Google Scholar
• Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell–encoded cd80 and 4-1bbl induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13(12):1440–1449. doi:10.1038/nm1676.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. Tumor-Targeted T-cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119:4133–4141.
   PubMed Web of Science ®Google Scholar
• Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE. CD19 CAR T-cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol Ther-Oncolytics. 2018;8:41–51. doi:10.1016/j.omto.2017.12.003.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. Trucks: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154. doi:10.1517/14712598.2015.1046430.
   PubMed Web of Science ®Google Scholar
• Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21(22):5047–5056. doi:10.1158/1078-0432.CCR-15-0685.
   PubMed Web of Science ®Google Scholar
• Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T-cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. 2018;11(1):1–18. doi:10.1186/s13045-018-0568-6.
   PubMedGoogle Scholar
• Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T-cells. Br J Cancer. 2019;120(1):26–37. doi:10.1038/s41416-018-0325-1.
   PubMed Web of Science ®Google Scholar
• Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang C-H, Saso K, Butler MO, Minden MD, Hirano N. A novel chimeric antigen receptor containing a jak–stat signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352–359. doi:10.1038/nm.4478.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA network open. 2020;3(4): e202072-e. doi:10.1001/jamanetworkopen.2020.2072
   Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M. Genetically targeted T-cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18):5426–5435. doi:10.1158/1078-0432.CCR-07-0674.
   PubMed Web of Science ®Google Scholar
• Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724–740. doi:10.1016/j.cell.2017.01.016.
   PubMed Web of Science ®Google Scholar
• Moreno C, Haynie C, Johnson A, Weber KS. Alternative CAR Therapies: recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. Biomedicines. 2022;10(7):1493. doi:10.3390/biomedicines10071493.
   PubMed Web of Science ®Google Scholar
• Savanur MA, Weinstein-Marom H, Gross G. Implementing logic gates for safer immunotherapy of cancer. Front Immunol. 2021;12:4678. doi:10.3389/fimmu.2021.780399.
   Web of Science ®Google Scholar
• Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ. Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In vivo. Cancer Immunol Res. 2013;1(1):43–53. doi:10.1158/2326-6066.CIR-13-0008.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T-cells. Nat Biotechnol. 2013;31(1):71–75. doi:10.1038/nbt.2459.
   PubMed Web of Science ®Google Scholar
• Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, Yuan CM, Haso W, Shern JF, Shah NN, et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther-Oncolytics. 2018;11:127–137. doi:10.1016/j.omto.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther-Nucleic Acids. 2013;2:e105. doi:10.1038/mtna.2013.32.
   PubMedGoogle Scholar
• Fedorov VD, Themeli M, Sadelain M. PD-1–and CTLA-4–based inhibitory chimeric antigen receptors (iCars) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172. doi:10.1126/scitranslmed.3006597.
   PubMed Web of Science ®Google Scholar
• Haubner S, Mansilla-Soto J, Nataraj S, He X, Park JH, Wang X, Rivière I, Sadelain M. IF-Better Gating: combinatorial Targeting and Synergistic Signaling for Enhanced CAR T-cell Efficacy. Blood. 2021;138(Supplement 1):2774. doi:10.1182/blood-2021-149263.
   Google Scholar
• Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T-cell responses. Cell. 2018;173(6):1426–38. e11. doi:10.1016/j.cell.2018.03.038.
   PubMed Web of Science ®Google Scholar
• Cho JH, Okuma A, Sofjan K, Lee S, Collins JJ, Wong WW. Engineering advanced logic and distributed computing in human CAR immune cells. Nat Commun. 2021;12(1):1–14. doi:10.1038/s41467-021-21078-7.
   PubMed Web of Science ®Google Scholar
• Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim W. Precision tumor recognition by T-cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770–779. doi:10.1016/j.cell.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, Lim WA. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell. 2016;164(4):780–791. doi:10.1016/j.cell.2016.01.012.
   PubMed Web of Science ®Google Scholar
• Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al. SynNotch-CAR T-cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378. doi:10.1126/scitranslmed.abe7378.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Hoffmann A, Bergmann R, Koristka S, Berndt N, Arndt C, Rodrigues Loureiro L, Kittel-Boselli E, Mitwasi N, Kegler A, et al. Versatile chimeric antigen receptor platform for controllable and combinatorial T-cell therapy. Oncoimmunology. 2020;9(1):1785608. doi:10.1080/2162402X.2020.1785608.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Hoffmann A, Kittel-Boselli E, Bergmann R, Koristka S, Berndt N, Arndt C, Loureiro LR, Mitwasi N, Jureczek J, et al. A Novel Revcar Platform for Switchable and Gated Tumor Targeting. Blood. 2019;134:5611. doi:10.1182/blood-2019-128436.
   Web of Science ®Google Scholar
• Salzer B, Schueller CM, Zajc CU, Peters T, Schoeber MA, Kovacic B, Buri MC, Lobner E, Dushek O, Huppa JB, et al. Engineering AvidCars for combinatorial antigen recognition and reversible control of CAR function. Nat Commun. 2020;11(1):1–16. doi:10.1038/s41467-020-17970-3.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu G, Wang J, Zheng Z-Y, Jia L, Rui W, Huang D, Zhou Z-X, Zhou L, Wu X, et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021;13(586):eabb5191. doi:10.1126/scitranslmed.abb5191.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang X, Zhou Z, Liu Y, Yu L, Jia L, Yang J, Li J, Yu H, Li W, et al. A novel adoptive synthetic tcr and antigen receptor (star) T-Cell therapy for B-Cell acute lymphoblastic leukemia. Am J Hematol. 2022;97(8):992–1004. doi:10.1002/ajh.26586.
   PubMed Web of Science ®Google Scholar
• Yee C. The use of endogenous T-cells for adoptive transfer. Immunol Rev. 2014;257(1):250–263. doi:10.1111/imr.12134.
   PubMed Web of Science ®Google Scholar
• Miliotou AN, Papadopoulou LC. Car T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19(1):5–18. doi:10.2174/1389201019666180418095526.
   PubMed Web of Science ®Google Scholar
• Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M. Allogeneic lymphocyte-licensed DCs expand T-cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther-Met Clin Dev. 2014;1:14001. doi:10.1038/mtm.2014.1.
   PubMed Web of Science ®Google Scholar
• Powell JD, Brennan AL, Zheng Z, Huynh H, Cotte J, Levine BL. Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy. 2009;11(7):923–935. doi:10.3109/14653240903188921.
   PubMed Web of Science ®Google Scholar
• Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ. Adoptive therapy with chimeric antigen receptor–modified T cells of defined subset composition. Cancer J. 2014;20(2):141. doi:10.1097/PPO.0000000000000036.
   PubMed Web of Science ®Google Scholar
• Cordes N, Kolbe C, Lock D, Holzer T, Althoff D, Schäfer D, Blaeschke F, Kotter B, Karitzky S, Rossig C, et al. Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells. Mol Ther-Met Clin Dev. 2021;21:42–53. doi:10.1016/j.omtm.2021.02.013.
   PubMed Web of Science ®Google Scholar
• Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D. Safe engineering of CAR T-cells for adoptive cell therapy of cancer using long‐term episomal gene transfer. Embo Mol Med. 2016;8(7):702–711. doi:10.15252/emmm.201505869.
   PubMed Web of Science ®Google Scholar
• Jensen TI, Axelgaard E, Bak RO. Therapeutic gene editing in haematological disorders with CRISPR/Cas9. Br J Haematol. 2019;185(5):821–835. doi:10.1111/bjh.15851.
   PubMed Web of Science ®Google Scholar
• DeWitt MA, Corn JE, Carroll D. Genome editing via delivery of Cas9 ribonucleoprotein. Methods. 2017;121:9–15. doi:10.1016/j.ymeth.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Frank AM, Braun AH, Scheib L, Agarwal S, Schneider IC, Fusil F, Perian S, Sahin U, Thalheimer FB, Verhoeyen E, et al. Combining T-cell-specific activation and In vivo gene delivery through CD3-targeted lentiviral vectors. Blood Adv. 2020;4(22):5702–5715. doi:10.1182/bloodadvances.2020002229.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Hanauer JD, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ. In vivo generation of CAR T-cells selectively in human CD4+ lymphocytes. Mol Ther. 2020;28(8):1783–1794. doi:10.1016/j.ymthe.2020.05.005.
   PubMed Web of Science ®Google Scholar
• Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RR, Danisch S, Costa C, Wels WS, Modlich U, Stripecke R, et al. In vivo generation of human CD 19- CAR T cells results in B-cell depletion and signs of cytokine release syndrome. Embo Mol Med. 2018;10(11):e9158. doi:10.15252/emmm.201809158.
   PubMed Web of Science ®Google Scholar
• Levine BL. Personalized cell-based medicine: activated and expanded T-cells for adoptive immunotherapy. Bioprocess J. 2007;6(2):14. doi:10.12665/J62.Levine.
   Google Scholar
• Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T-cell therapy. Mol Ther-Met Clin Dev. 2017;4:92–101. doi:10.1016/j.omtm.2016.12.006.
   PubMed Web of Science ®Google Scholar
• Mock U, Nickolay L, Cheung G-K, Zhan H, Peggs K, Johnston IC, Kaiser A, Pule M, Thrasher A, Qasim W, et al. Automated lentiviral transduction of T-cells with CARs using the CliniMACS Prodigy. Blood. 2015;126(23):2043. doi:10.1182/blood.V126.23.2043.2043.
   Web of Science ®Google Scholar
• Abou-el-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Scalable manufacturing of CAR T-cells for cancer ImmunotherapyClinical production of CAR T-cells. Blood Cancer Discovery. 2021;2(5):408–422. doi:10.1158/2643-3230.BCD-21-0084.
   PubMedGoogle Scholar
• Alzubi J, Lock D, Rhiel M, Schmitz S, Wild S, Mussolino C, Hildenbeutel M, Brandes C, Rositzka J, Lennartz S, et al. Automated generation of gene-edited CAR T cells at clinical scale. Mol Ther-Met Clin Dev. 2021;20:379–388. doi:10.1016/j.omtm.2020.12.008.
   PubMed Web of Science ®Google Scholar
• Makita S, Imaizumi K, Kurosawa S, Tobinai K. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs Context. 2019;8:1–14. doi:10.7573/dic.212567.
   Google Scholar
• Hartmann J, Schüßler‐lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T-cells—challenges and opportunities in translating innovative treatment concepts. Embo Mol Med. 2017;9(9):1183–1197. doi:10.15252/emmm.201607485.
   PubMed Web of Science ®Google Scholar
• Wall D, Krueger J. Chimeric antigen receptor T-cell therapy comes to clinical practice. Current Oncol. 2020;27(s2):115–123. doi:10.3747/co.27.5283.
   Google Scholar
• Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nat Clin Pract Oncol. 2006;3(12):668–681. doi:10.1038/ncponc0666.
   PubMedGoogle Scholar
• Turtle CJ, Hanafi L-A, Berger C, Sommermeyer D, Pender B, Robinson EM, Melville K, Budiarto TM, Steevens NN, Chaney C, et al. Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood. 2015;126(23):3773. doi:10.1182/blood.V126.23.3773.3773.
   Web of Science ®Google Scholar
• Ghilardi G, Chong E, Svoboda J, Wohlfarth P, Nasta S, Williamson S, Landsburg JD, Gerson JN, Barta SK, Pajarillo R. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol. 2022. doi:10.1016/j.annonc.2022.05.521.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T-cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu M-F, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, et al. Anti-CD30 CAR-T-cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794. doi:10.1200/JCO.20.01342.
   PubMed Web of Science ®Google Scholar
• Dawicki W, Allen KJ, Garg R, Geoghegan EM, Berger MS, Ludwig DL, Dadachova E. Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy. Oncotarget. 2020;11(39):3571. doi:10.18632/oncotarget.27731.
   PubMedGoogle Scholar
• Nath R, Geoghegan EM, Ulrickson ML, Spross JA, Lichtenstein RH, Konerth S, Fisher DR, Liang Q, Ludwig D, Reddy V, et al. Sierra clinical trial dosimetry results support low dose anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for targeted lymphodepletion prior to adoptive cell therapy. Blood. 2019;134:1958. doi:10.1182/blood-2019-128838.
   Web of Science ®Google Scholar
• Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T-cell therapy. Nat Rev Clin Oncol. 2019;16(1):45–63. doi:10.1038/s41571-018-0075-2.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31–46. doi:10.1038/nrclinonc.2017.128.
   PubMed Web of Science ®Google Scholar
• Su X, Vale R. Mechanisms of chimeric antigen receptor (CAR) signaling during T-cell activation. Biophys J. 2018;114(3):107a–108a. doi:10.1016/j.bpj.2017.11.625.
   Web of Science ®Google Scholar
• Yu JX, Hubbard-Lucey VM, Tang J. The global pipeline of cell therapies for cancer. Nat Rev Drug Discov. 2019;18(11):821–822. doi:10.1038/d41573-019-00090-z.
   PubMed Web of Science ®Google Scholar
• Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017;130:2594–2602.
   PubMed Web of Science ®Google Scholar
• Abbasi MH, Riaz A, Khawar MB, Farooq A, Majid A, Sheikh N. CAR-T-Cell therapy: present progress and future strategies. Biomed Res Ther. 2022;9(2):4920–4929. doi:10.15419/bmrat.v9i2.726.
   Web of Science ®Google Scholar
• Cantrell DA. T-Cell antigen receptor signal transduction. Immunology. 2002;105(4):369. doi:10.1046/j.1365-2567.2002.01391.x.
   PubMed Web of Science ®Google Scholar
• Cullen S, Martin S. Mechanisms of granule-dependent killing. Cell Death Differ. 2008;15(2):251–262. doi:10.1038/sj.cdd.4402244.
   PubMed Web of Science ®Google Scholar
• de Saint Basile G, Ménasché G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol. 2010;10(8):568–579. doi:10.1038/nri2803.
   PubMed Web of Science ®Google Scholar
• Nagata S, Tanaka M. Programmed cell death and the immune system. Nat Rev Immunol. 2017;17(5):333–340. doi:10.1038/nri.2016.153.
   PubMed Web of Science ®Google Scholar
• Davenport AJ, Jenkins MR, Cross RS, Yong CS, Prince HM, Ritchie DS, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ, et al. CAR-T-Cells inflict sequential killing of multiple tumor targeT-cells. Cancer Immunol Res. 2015;3(5):483–494. doi:10.1158/2326-6066.CIR-15-0048.
   PubMed Web of Science ®Google Scholar
• Nai Y, Du L, Shen M, Li T, Huang J, Han X, Luo F, Wang W, Pang D, Jin A, et al. TRAIL-R1-Targeted CAR-T-cells exhibit dual antitumor efficacy. Front Mol Biosci. 2021;8. doi:10.3389/fmolb.2021.756599
   Web of Science ®Google Scholar
• Tang X-J, Sun X-Y, Huang K-M, Zhang L, Yang Z-S, Zou D-D, Wang B, Warnock GL, Dai L-J, Luo J, et al. Therapeutic potential of CAR-T-cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget. 2015;6(42):44179. doi:10.18632/oncotarget.6175.
   PubMedGoogle Scholar
• Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol. 2015;27(6):466. doi:10.1097/CCO.0000000000000232.
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Wilgenhof S, Haanen JB. Adoptive cellular therapies: the current landscape. Virchows Archiv. 2019;474(4):449–461. doi:10.1007/s00428-018-2484-0.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T-cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–4102.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM. Long-Term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. doi:10.1016/S1470-2045(18)30864-7.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi:10.1056/NEJMoa1914347.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T-cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al. A phase I study on adoptive immunotherapy using gene-modified T-cells for ovarian cancer. Clin Cancer Res. 2006;12(20):6106–6115. doi:10.1158/1078-0432.CCR-06-1183.
   PubMed Web of Science ®Google Scholar
• Lamers C, Sleijfer S, Vulto AG, Kruit W, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20–2. doi:10.1200/JCO.2006.05.9964.
   PubMedGoogle Scholar
• Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–2569. doi:10.1056/NEJMoa1610497.
   PubMed Web of Science ®Google Scholar
• Sengsayadeth S, Savani BN, Oluwole O, Dholaria B. Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice. Ejhaem. 2022;3:6–10. doi:10.1002/jha2.338.
   PubMedGoogle Scholar
• FDA. Novel Drugs Approved by the FDA, 2011–2017. 2018.
   Google Scholar
• Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T-cells targeting CD19. Cytotherapy. 2020;22(2):57–69. doi:10.1016/j.jcyt.2019.12.004.
   PubMed Web of Science ®Google Scholar
• Prasad V. Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018;15(1):11–12. doi:10.1038/nrclinonc.2017.156.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Uddin S, Steinhoff M. Car-T-Cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large b-cell lymphomas. Int J Mol Sci. 2020;21(11):3906. doi:10.3390/ijms21113906.
   PubMed Web of Science ®Google Scholar
• Laura Joszt M. FDA Approves Tisa-Cel for Third Indication, r/r Follicular Lymphoma. Innovation Multi Care. May 2022.
   Google Scholar
• Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P. Standard-Of-Care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119. doi:10.1200/JCO.19.02104.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Chavez JC, Sehgal A, William BM, Munoz J, Salles GA, Casulo C, Munshi PN, Maloney DG, De Vos S, et al. Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24). USA: American Society of Clinical Oncology; 2021.
   Google Scholar
• FDA. FDA approves FirsT-cell-based gene therapy for adult patients with relapsed or refractory mcl. 2020.
   Google Scholar
• FDA. FDA approval of Tecartus (brexucabtagene autoleucel) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. DISCO Burst Edition. 2021.
   Google Scholar
• Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. The Lancet. 2021;398(10299):491–502. doi:10.1016/S0140-6736(21)01222-8.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma. 2021.
   Google Scholar
• Kharfan-Dabaja MA, Yassine F, Moustafa MA, Iqbal M, Murthy H. Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: what is the evidence? Hematol Oncol Stem Cell Ther. 2021. doi:10.1016/j.hemonc.2021.09.004.
   Google Scholar
• Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. 2020;396(10254):839–852. doi:10.1016/S0140-6736(20)31366-0.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson JL, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi:10.1056/NEJMoa2024850.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N. KarMma-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021;11(6):1–9. doi:10.1038/s41408-021-00507-2.
   PubMed Web of Science ®Google Scholar
• FDAFDA approval of carvykti (ciltacabtagene autoleucel) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-cd38 monoclonal antibody. FDA DISCO Burst Edition. 2022.
   Google Scholar
• Madduri D, Berdeja JG, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, O’Donnell E, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, in relapsed/refractory multiple myeloma. Blood. 2020;136:22–25. doi:10.1182/blood-2020-136307.
   Web of Science ®Google Scholar
• King AC, Orozco JS. Axicabtagene ciloleucel: the first FDA-approved CAR T-cell therapy for relapsed/refractory large B-cell lymphoma. J Adv Pract Oncol. 2019;10(8):878. doi:10.6004/jadpro.2019.10.8.9.
   PubMedGoogle Scholar
• Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, Lacey SF, Levine BL, Melenhorst JJ, Motley L, et al. Durable remissions in children with relapsed/refractory all treated with T-cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood. 2015;126(23):681. doi:10.1182/blood.V126.23.681.681.
   Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-Refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540. doi:10.1200/JCO.2014.56.2025.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-Term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. doi:10.1016/S1470-2045(21)00375-2.
   PubMed Web of Science ®Google Scholar
• Lemal R, Tournilhac O. State-Of-The-Art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer. 2019;7(1):1–6. doi:10.1186/s40425-019-0686-x.
   PubMed Web of Science ®Google Scholar
• FDAFDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. 2022.
   Google Scholar
• FDAFDA approves axicabtagene ciloleucel for large B-cell lymphoma. 2017.
   Google Scholar
• Elsawy M, Chavez JC, Avivi I, Larouche J-F, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, et al., editors. Patient-Reported Outcomes (PROs) in Zuma-7, a phase 3, randomized, open-label study evaluating the efficacy of Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care (SOC) therapy in patients with relapsed/refractory Large B-Cell Lymphoma (LBCL) 2022 Tandem Meetings|Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; 2022: Tandem Meetings; United States.
   Google Scholar
• Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735–742. doi:10.1038/s41591-022-01731-4.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138. doi:10.1172/JCI85309.
   PubMed Web of Science ®Google Scholar
• De Bousser E, Callewaert N, Festjens N. T-cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T-cell therapy. Cancers. 2021;13(23):6067. doi:10.3390/cancers13236067.
   PubMed Web of Science ®Google Scholar
• Maldini CR, Ellis GI, Riley JL. Car T-cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol. 2018;18(10):605–616. doi:10.1038/s41577-018-0042-2.
   PubMed Web of Science ®Google Scholar
• Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T-cells against solid cancers. J Hematol Oncol. 2020;13(1):1–16. doi:10.1186/s13045-020-00890-6.
   PubMed Web of Science ®Google Scholar
• Singh N, Frey NV, Grupp SA, Maude SL. Car T-cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr Treat Options Oncol. 2016;17(6):1–11. doi:10.1007/s11864-016-0406-4.
   PubMed Web of Science ®Google Scholar
• Wei J, Han X, Bo J, Han W. Target selection for CAR-T therapy. J Hematol Oncol. 2019;12(1):1–9. doi:10.1186/s13045-019-0758-x.
   PubMedGoogle Scholar
• Schultz L, Mackall C. Driving CAR T-cell translation forward. Sci Transl Med. 2019;11(481):eaaw2127. doi:10.1126/scitranslmed.aaw2127.
   PubMed Web of Science ®Google Scholar
• Almåsbak H, Aarvak T, Vemuri MC. Car T-cell therapy: a game changer in cancer treatment. J Immunol Res. 2016;2016:1–10. doi:10.1155/2016/5474602.
   Web of Science ®Google Scholar
• Rennert P, Su L, Dufort F, Birt A, Sanford T, Wu L, Ambrose C, Lobb R. A novel CD19-anti-CD20 bridging protein prevents and reverses CD19-negative relapse from CAR19 T cell treatment in vivo. Blood. 2019;134:252. doi:10.1182/blood-2019-130654.
   PubMedGoogle Scholar
• Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al. CD22-Targeted CAR T-cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–28. doi:10.1038/nm.4441.
   PubMed Web of Science ®Google Scholar
• Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, et al. Donor-Derived CD7 chimeric antigen receptor T-cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39(30):3340–3351. doi:10.1200/JCO.21.00389.
   PubMed Web of Science ®Google Scholar
• Kirtane K, Elmariah H, Chung CH, Abate-Daga D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021;9(7):e002723. doi:10.1136/jitc-2021-002723.
   PubMed Web of Science ®Google Scholar
• Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, Shomali N, Chartrand MS, Pathak Y, Jarahian M, et al. Car T-cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):1–16. doi:10.1186/s13287-020-02128-1.
   PubMed Web of Science ®Google Scholar
• Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, Yeung CCS, Sheih A, Pender BS, Hawkins RM, et al. Feasibility and efficacy of CD19-targeted CAR T-cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650–1660. doi:10.1182/blood.2019002936.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML. NKG2D-Based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica. 2018;103(9):e424. doi:10.3324/haematol.2017.186742.
   PubMed Web of Science ®Google Scholar
• Shadman M, Yeung C, Redman MW, Lee SY, Lee DH, Ramachandran A, Ra S, Marzbani EA, Graf SA, Warren EH, et al. Third generation CD20 targeted CAR T-cell therapy (MB-106) for treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2020;136(Supplement 1):38–39. doi:10.1182/blood-2020-136440.
   Google Scholar
• Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J, Baumeister SHC. Chimeric antigen receptor T-cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Front Immunol. 2020;11:580328. doi:10.3389/fimmu.2020.580328.
   PubMed Web of Science ®Google Scholar
• Maiorova V, Mollaev MD, Vikhreva P, Kulakovskaya E, Pershin D, Chudakov DM, Kibardin A, Maschan MA, Larin S. Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T-cells Successfully Target Flt3 on AML Cell Lines. Vaccines. 2021;9(11):1238. doi:10.3390/vaccines9111238.
   Web of Science ®Google Scholar
• Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, et al. Cml hematopoietic stem cells expressing il1rap can be targeted by chimeric antigen receptor–engineered T cells. Cancer Res. 2019;79(3):663–675. doi:10.1158/0008-5472.CAN-18-1078.
   PubMed Web of Science ®Google Scholar
• Cui Q, Qian C, Xu N, Kang L, Dai H, Cui W, Song B, Yin J, Li Z, Zhu X, et al. CD38-Directed CAR-T-cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):1–5. doi:10.1186/s13045-021-01092-4.
   PubMed Web of Science ®Google Scholar
• Hill L, Rouce RH, Smith TS, Yang L, Srinivasan M, Zhang H, Perconti S, Mehta B, Dakhova O, Randall J, et al. CD5 CAR T-cells for treatment of patients with relapsed/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity. Biol Blood Marrow Transplant. 2020;26(3):S237. doi:10.1016/j.bbmt.2019.12.482.
   Web of Science ®Google Scholar
• Cheng J, Chen G, Lv H, Xu L, Liu H, Chen T, Qu L, Wang J, Cheng L, Hu S, et al. CD4-Targeted T-cells rapidly induce remissions in mice with T-cell Lymphoma. Biomed Res Int. 2021;2021. doi:10.1155/2021/6614784
   Web of Science ®Google Scholar
• Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983–992.
   PubMed Web of Science ®Google Scholar
• Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Künkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, et al. Locoregional infusion of HER2-specific CAR T-cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021;27(9):1544–1552. doi:10.1038/s41591-021-01404-8.
   PubMed Web of Science ®Google Scholar
• Shah NN, Fry TJ. Mechanisms of resistance to CAR T-cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385. doi:10.1038/s41571-019-0184-6.
   PubMed Web of Science ®Google Scholar
• Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT, Morris JS, Luong A, Martínez-Paniagua MA, Sanber K, et al. Car T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021;35(1):75–89. doi:10.1038/s41375-020-0792-2.
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Baniewicz D, White C, Talekar MK, Shaw PA, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T-cells in children and young adults with relapsed/refractory acute lymphoblastic leukemia. Blood. 2016;128(22):217. doi:10.1182/blood.V128.22.217.217.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T-Cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi:10.1126/scitranslmed.3002842.
   PubMed Web of Science ®Google Scholar
• Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–1506. doi:10.1038/s41591-018-0146-z.
   PubMed Web of Science ®Google Scholar
• Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, Kron B, Russo A, Lehmann N, Roth L, et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40(5):187. doi:10.1097/CJI.0000000000000169.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015;5(12):1282–1295. doi:10.1158/2159-8290.CD-15-1020.
   PubMed Web of Science ®Google Scholar
• Gardner R, Wu D, Cherian S, Fang M, Hanafi L-A, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406–2410.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–1226. doi:10.1158/2159-8290.CD-18-0442.
   PubMed Web of Science ®Google Scholar
• Green DJ, Pont M, Sather BD, Cowan AJ, Turtle CJ, Till BG, Nagengast AM, Libby EN, Becker PS, Coffey DG, et al. Fully human BCMA targeted chimeric antigen receptor T-cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood. 2018;132(Supplement 1):1011. doi:10.1182/blood-2018-99-117729.
   Web of Science ®Google Scholar
• Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, et al. T Cells genetically modified to express an Anti–B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267. doi:10.1200/JCO.2018.77.8084.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, et al. B cell maturation antigen–specific car T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210–2221. doi:10.1172/JCI126397.
   PubMed Web of Science ®Google Scholar
• Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged persistence of chimeric antigen receptor (CAR) T-cell in adoptive cancer immunotherapy: challenges and ways forward. Front Immunol. 2020;11:702. doi:10.3389/fimmu.2020.00702.
   PubMed Web of Science ®Google Scholar
• Li D, Li N, Zhang Y-F, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, et al. Persistent polyfunctional chimeric antigen receptor T-cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology. 2020;158(8):2250–65. e20. doi:10.1053/j.gastro.2020.02.011.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015;33:9–15. doi:10.1016/j.coi.2015.01.002.
   PubMed Web of Science ®Google Scholar
• Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75(17):3505–3518. doi:10.1158/0008-5472.CAN-15-0139.
   PubMed Web of Science ®Google Scholar
• McGowan E, Lin Q, Ma G, Yin H, Chen S, Lin Y. PD-1 disrupted CAR-T-cells in the treatment of solid tumors: promises and challenges. Biomed Pharmacother. 2020;121:109625. doi:10.1016/j.biopha.2019.109625.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang L, Predina J, Han R, Beier UH, Wang LCS, Kapoor V, Bhatti TR, Akimova T, Singhal S. Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity. Nat Med. 2013;19(9):1173–1177. doi:10.1038/nm.3286.
   PubMed Web of Science ®Google Scholar
• Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, et al. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T-cell exhaustion. Nat Immunol. 2019;20(6):724–735. doi:10.1038/s41590-019-0346-9.
   PubMed Web of Science ®Google Scholar
• Seo H, Chen J, González-Avalos E, Samaniego-Castruita D, Das A, Wang YH, López-Moyado IF, Georges RO, Zhang W, Onodera A, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 + T cell exhaustion. Proc Nat Acad Sci. 2019;116(25):12410–12415. doi:10.1073/pnas.1905675116.
   PubMed Web of Science ®Google Scholar
• Nabe S, Yamada T, Suzuki J, Toriyama K, Yasuoka T, Kuwahara M, Shiraishi A, Takenaka K, Yasukawa M, Yamashita M, et al. Reinforce the antitumor activity of CD 8 + T cells via glutamine restriction. Cancer Sci. 2018;109(12):3737–3750. doi:10.1111/cas.13827.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T-cells, and universal CAR T-cells. J Hematol Oncol. 2018;11(1):1–9. doi:10.1186/s13045-018-0677-2.
   PubMedGoogle Scholar
• Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol. 2019;12(1):1–9. doi:10.1186/s13045-019-0763-0.
   PubMedGoogle Scholar
• Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T-cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–167. doi:10.1038/s41571-019-0297-y.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH, et al. Dominant-Negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855–1866. doi:10.1016/j.ymthe.2018.05.003.
   PubMed Web of Science ®Google Scholar
• Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28(9):513–527. doi:10.1038/s41434-021-00246-w.
   PubMed Web of Science ®Google Scholar
• Abreu TR, Fonseca NA, Gonçalves N, Moreira JN. Current challenges and emerging opportunities of CAR-T-cell therapies. J Controlled Release. 2020;319:246–261. doi:10.1016/j.jconrel.2019.12.047.
   PubMed Web of Science ®Google Scholar
• Zhao L, Cao YJ. Engineered T-cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250. doi:10.3389/fimmu.2019.02250.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55. doi:10.1016/j.blre.2018.11.002.
   PubMed Web of Science ®Google Scholar
• Si S, Teachey DT. Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag. 2020;16:705. doi:10.2147/TCRM.S223468.
   PubMed Web of Science ®Google Scholar
• Diorio C, Vatsayan A, Talleur AC, Annesley C, Jaroscak JJ, Shalabi H, Ombrello AK, Hudspeth M, Maude SL, Gardner RA, et al. Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. Blood Adv. 2022;6(11):3398–3403. doi:10.1182/bloodadvances.2022006983.
   PubMed Web of Science ®Google Scholar
• Park JH, Sauter CS, Palomba ML, Shah GL, Dahi PB, Lin RJ, Scordo M, Batlevi CL, Perales M-A, Kane P, et al. A phase ii study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T-cell therapy for relapsed or refractory lymphoma. Blood. 2021;138:96. doi:10.1182/blood-2021-150431.
   Web of Science ®Google Scholar
• Oliai C, Crosetti A, De Vos S, Eradat H, Mead MD, Larson SM, Tsai S, Liu A, Khachatrian G, Hannigan C, et al. IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome. United States: Wolters Kluwer Health; 2021.
   Google Scholar
• Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B. CAR-T-Cell therapy and infection: a review. Expert Rev Anti Infect Ther. 2021;19(6):749–758. doi:10.1080/14787210.2021.1855143.
   PubMed Web of Science ®Google Scholar
• Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C. HSV-Tk gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719–1724. doi:10.1126/science.276.5319.1719.
   PubMed Web of Science ®Google Scholar
• Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Co-Expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007;110:2793–2802.
   PubMed Web of Science ®Google Scholar
• C-Y W, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T-cells through a small molecule–gated chimeric receptor. Science. 2015;350(6258):aab4077. doi:10.1126/science.aab4077.
   PubMed Web of Science ®Google Scholar
• Frankel SR, Baeuerle PA. Targeting T-cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17(3):385–392. doi:10.1016/j.cbpa.2013.03.029.
   PubMed Web of Science ®Google Scholar
• Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG, Pacheco KZB, Malipatlolla M, Xu P, Hui JH, et al. Enhanced safety and efficacy of protease-regulated CAR-T-cell receptors. Cell. 2022;185(10):1745–63. e22. doi:10.1016/j.cell.2022.03.041.
   PubMed Web of Science ®Google Scholar
• Lee SM, Kang CH, Choi SU, Kim Y, Hwang JY, Jeong HG, Park CH. A chemical switch system to modulate chimeric antigen receptor T-cell activity through proteolysis-targeting chimaera technology. Acs Synth Biol. 2020;9(5):987–992. doi:10.1021/acssynbio.9b00476.
   PubMed Web of Science ®Google Scholar
• Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant. 2020;55(9):1706–1715. doi:10.1038/s41409-020-0956-8.
   PubMed Web of Science ®Google Scholar
• Zhang C, He J, Liu L, Wang J, Wang S, Liu L, Ge J, Gao L, Gao L, Kong P, et al. Novel CD19 chimeric antigen receptor T-cells manufactured next-day for acute lymphoblastic leukemia. Blood Cancer J. 2022;12(6):1–9. doi:10.1038/s41408-022-00688-4.
   PubMed Web of Science ®Google Scholar
• Ardigen2021. CAR-T-Cell therapies: limitations and improvement strategies. Poland: Ardigen BLOG.
   Google Scholar
• Novartis. Charging towards the next-generation of CAR-T. 2022.
   Google Scholar
• Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, Zörnig I, Jäger D, Schmidt P, Harbottle RP, et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T-cells. Science Adv. 2021;7(16):eabf1333. doi:10.1126/sciadv.abf1333.
   PubMed Web of Science ®Google Scholar
• Depil S, Duchateau P, Grupp S, Mufti G, Poirot L. ‘Off-The-Shelf’allogeneic CAR T-cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–199. doi:10.1038/s41573-019-0051-2.
   PubMed Web of Science ®Google Scholar
• Cutmore LC, Marshall JF. Current perspectives on the use of off the shelf CAR-T/NK cells for the treatment of cancer. Cancers. 2021;13(8):1926. doi:10.3390/cancers13081926.
   PubMed Web of Science ®Google Scholar
• Elavia N, McManus A, Highfill SL, Ren J, Shah NN, Fry TJ, Brudno J, Kochenderfer JN, Stroncek D, Panch SR. The post-thaw recovery of cryopreserved chimeric antigen receptor (CAR) T-cells during manufacture is better than that of cryopreserved peripheral blood CD3+ cells. Blood. 2017;130:4475.
   Web of Science ®Google Scholar
• Tay A. Cryopreservation to Improve Cell Manufacturing and Biobanking: as adoptive cell therapies and stem cell therapies come to be applied more generally, cryopreservation technology must cope with quality and supply challenges. Genet Eng Biotechnol News. 2020;40(S5):S10–S2. doi:10.1089/gen.40.S5.05.
   Google Scholar
• Harrison RP, Zylberberg E, Ellison S, Levine BL. Chimeric antigen receptor–t-cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy. 2019;21(2):224–233. doi:10.1016/j.jcyt.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Sanber K, Savani B, Jain T. Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T-cells. Br J Haematol. 2021;195(5):660–668. doi:10.1111/bjh.17544.
   PubMed Web of Science ®Google Scholar